We are live on
!
Find out more
ANI Pharmaceuticals
ANIP
ANIP
284 hedge funds and large institutions have $1.67B invested in ANI Pharmaceuticals in 2025 Q4 according to their latest regulatory filings, with 49 funds opening new positions, 114 increasing their positions, 77 reducing their positions, and 32 closing their positions.
New
Increased
Maintained
Reduced
Closed
53% more first-time investments, than exits
New positions opened: 49 | Existing positions closed: 32
48% more repeat investments, than reductions
Existing positions increased: 114 | Existing positions reduced: 77
6% more funds holding
Funds holding: 269 → 284 (+15)
0.16% more ownership
Funds ownership: 94.1% → 94.26% (+0.16%)
11% less capital invested
Capital invested by funds: $1.87B → $1.67B (-$198M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
54% less call options, than puts
Call options by funds: $11.5M | Put options by funds: $25.2M
Holders
284
Holders Change
+15
Holders Change %
+5.58%
% of All Funds
3.45%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.01%
New
49
Increased
114
Reduced
77
Closed
32
Calls
$11.5M
Puts
$25.2M
Net Calls
-$13.8M
Net Calls Change
-$13.8M
Top Buyers
Top Sellers
| 1 |
Citadel Advisors
Miami,
Florida
|
-$48.5M |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$38M |
| 3 |
RCMNY
Rubric Capital Management (New York)
New York
|
-$31.5M |
| 4 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
-$26.7M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
-$24.1M |
